There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small ...

Medically reviewed by Susan Russell, MDMedically reviewed by Susan Russell, MD Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80-85% of all cases.

This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer. Lung cancer is the commonest cancer ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of patients will be ...

The Wisconsin Cancer Collaborative has published its most recent data about the number of lung cancer cases in Wisconsin.

The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.

We look forward to progressing enrollment and evaluating the safety and efficacy of the triplet combination in treating KRAS G12C mutant non-small cell lung cancer.” RAMP 203 Clinical Update As ...

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...